Nextsource CEO Robert Dicrisci, pictured, says they base pricing on “product-development costs, regulatory-agency fees, and the benefit the treatment delivers to patients.” As it didn’t develop the drug and regulatory fees are not up 1,400%, that leaves the last part of his formulation. It is, in all fairness, a good way of suggesting that your life is surely worth every penny you have.
Source: Price of 40-year-old cancer drug raised from $50 to $768 a pill / Boing Boing
Fucking assholes.
Advertisements Share this:
